Engineered Gut Bacteria With Calprotectin-Triggered Therapeutic Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammatory bowel disease (IBD) involve systemic administration of anti-inflammatory cytokines and antibodies, leading to severe side effects due to immunosuppression, and there is a need for localized and targeted therapeutic delivery in the gastrointestinal tract.

Innovation Solution

Engineered E. coli strains, such as E. coli Nissle 1917, are designed to produce and selectively release therapeutic proteins like anti-TNFα antibodies and IL-10 in response to calprotectin, an IBD biomarker, using a phage-derived lysis element linked to a calprotectin-responsive promoter, ensuring targeted delivery during inflammatory flares.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If systemic administration of anti-inflammatory cytokines and antibodies is used to treat IBD, then therapeutic efficacy is improved, but severe side effects due to immunosuppression occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidside effects from immunosuppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by engineering bacteria to deliver therapeutics locally at the site of inflammation in the GI tract rather than through systemic administration. The calprotectin-responsive promoter ensures that therapeutic proteins are expressed and released only in the specific location where calprotectin levels are elevated, providing localized treatment that avoids widespread immunosuppression throughout the body.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses engineered bacteria as an intermediary carrier to deliver therapeutic proteins to the target site. These bacteria act as living vehicles that respond to the inflammatory environment (calprotectin presence) and release therapeutics on-demand, mediating between the therapeutic agent and the disease site while avoiding systemic distribution and associated side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of stationary object

If continuous therapeutic delivery is maintained to control IBD, then disease management is improved, but unnecessary immunosuppression and side effects increase

Engineering Contradiction:

Improvecontinuous therapeutic deliveryVSAvoidunnecessary immunosuppression

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent implements dynamics by creating a responsive, condition-dependent therapeutic delivery system. The calprotectin-responsive promoter dynamically regulates therapeutic protein expression based on the presence of calprotectin, allowing the system to adapt to changing disease states. Therapeutics are delivered only when inflammation is detected (calprotectin present) and stopped when inflammation subsides, replacing continuous delivery with intelligent, demand-based delivery.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent incorporates feedback mechanisms where the inflammatory environment itself (calprotectin levels) serves as the signal to trigger or stop therapeutic delivery. The calprotectin-responsive promoter acts as a sensor that detects calprotectin presence and automatically regulates gene expression accordingly, creating a closed-loop system where the disease state directly controls the therapeutic response, eliminating the need for continuous indiscriminate delivery.

Inventive Principle:

Principle #23Feedback

3Object-affected harmful factors

If targeted therapeutic delivery using engineered bacteria is implemented, then systemic side effects are minimized, but device complexity increases

Engineering Contradiction:

Improvesystemic side effectsVSAvoidcomplexity of engineered bacterial system

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent applies self-service by engineering bacteria to autonomously sense and respond to the inflammatory environment without external control. The calprotectin-responsive promoter enables the bacteria to automatically detect calprotectin and trigger therapeutic protein expression and release independently, eliminating the need for external induction or complex control systems while achieving targeted delivery and minimizing side effects.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach minimizes systemic side effects by delivering therapeutics only when needed, providing localized treatment in the GI tract and effectively reducing inflammation without immunosuppression.

Implementation Method 1

a lysis element operably linked to a calprotectin-responsive promoter. The lysis element induces lysis of the bacterial host cell and release of the protein for treatment of gastrointestinal disease in the presence of calprotectin

Methodology Applied

Scientific EffectCalprotectin-responsive promoter activation: